SH‐PRO extract alleviates benign prostatic hyperplasia via ROS‐mediated activation of PARP/caspase 3 and inhibition of FOXO3a/AR/PSA signaling in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2022 at "Phytotherapy Research"
DOI: 10.1002/ptr.7626
Abstract: To target benign prostatic hyperplasia (BPH) as a common urinary disease in old men, in the current study, the antiproliferative and apoptotic mechanism of SH‐PRO, a mixture of Angelica gigas and Astragalus membranaceus (2:1), was… read more here.
Keywords: bph; foxo3a; psa; bph cells ... See more keywords
Upregulated Interleukin 21 Receptor Enhances Proliferation and Epithelial-Mesenchymal Transition Process in Benign Prostatic Hyperplasia
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2019.00004
Abstract: Background: Interleukins (ILs) and related chronic inflammation have been found to contribute to the development of benign prostatic hyperplasia (BPH) in recent decades. As a late member of the ILs family, IL-21 receptor (IL-21R) can… read more here.
Keywords: bph cells; benign prostatic; bph; cell ... See more keywords
6′-Sialyllactose Ameliorates In Vivo and In Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb–AR Pathway
Sign Up to like & getrecommendations! Published in 2019 at "Nutrients"
DOI: 10.3390/nu11092203
Abstract: Background: 6′-Sialyllactose (6SL) displays a wide range of the bioactive benefits, such as anti-proliferative and anti-angiogenic activities. However, the therapeutic effects of 6SL on benign prostatic hyperplasia (BPH) remain unknown. Methods: Six-week-old male Wistar rats… read more here.
Keywords: bph cells; benign prostatic; prb; bph ... See more keywords